Immune System News and Research

RSS

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

ImmunoCellular Therapeutics, Ltd. a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it will be presenting results from its clinical trial of ICT-107 at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.

21 May 2010

European researchers define research priorities in biogerontology

The quality of the medical care for geriatric patients is a major investment for society and must imperatively be a research priority in Europe. This is why 50 European researchers, met on May 17 - 19 in Brussels, to define the research priorities in the field of biogerontology for the next 10 to 15 years.

21 May 2010

New therapy program serves as foundation for ongoing clinical development

The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research.

21 May 2010

Researchers discover key gene that promotes development of common kidney cancer

Researchers at Mayo Clinic's campus in Florida have discovered a key gene that, when turned off, promotes the development of common kidney cancer. Their findings suggest that a combination of agents now being tested in other cancers may turn the gene back on, providing a much-needed therapy for the difficult-to-treat cancer.

21 May 2010

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.

21 May 2010

Vitamin D plays much wider role in people's life

Vitamin D is the sunshine vitamin - we make it when our skin is exposed to UV rays. In a perfect world everyone would eat fresh, organic foods, get outside, and enjoy a little sunshine all year round. But with today's busy lifestyles and concerns about skin cancer many people are vitamin D deficient and don't know it.

21 May 2010

HemaCare announces commercial cell therapy collection agreement with Dendreon

HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.

21 May 2010

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study

Amsterdam Molecular Therapeutics a world leader in gene therapy, today reported positive preclinical data from a study using an AAV gene therapy product to lower cholesterol.

21 May 2010

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Antigenics today announced that data from a multi-center Phase 1/2 clinical trial of Oncophage (vitespen) for recurrent high-grade glioma (brain cancer) was presented at the International Conference on Brain Tumor Research and Therapy. The study was conducted by the Brain Tumor Research Center at the University of California, San Francisco.

20 May 2010

Research and movement in future towards universal influenza virus vaccine

Researchers at Mt. Sinai School of Medicine have developed a novel influenza vaccine that could represent the next step towards a universal influenza vaccine eliminating the need for seasonal immunizations. They report their findings today in the inaugural issue of mBio-, the first online, open-access journal published by the American Society for Microbiology.

20 May 2010

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

20 May 2010

Live malaria parasites in the skin shut down immune responses and block vaccine function: Study

Why one after another new malaria vaccine tests well in the laboratory but fails in field trials has frustrated legions of malaria researchers, and has been the main stumbling block to malaria eradication. Now, a research team from Germany has unraveled that puzzle and shown that the problem is all about the skin and how it controls the immune system. The implications are profound.

20 May 2010

Update on Phase I clinical trials of Oncopore for treatment of cancer

The Norwegian pharmaceutical company Lytix Biopharma AS provided an update at the recent BIO conference in Chicago on Phase I clinical trials of Oncopore (LTX-315) for the treatment of cancer.

20 May 2010

Saint Louis University conducts research to find safe, effective vaccination for dengue

Sponsored by the National Institutes of Health, Saint Louis University's Center for Vaccine Development is conducting research of an investigational vaccine designed to prevent people from contracting dengue, a potentially lethal virus that has rapidly spread around the world.

20 May 2010

New study shows CDPK1 controls toxoplasma's ability to secrete microneme proteins

Researchers at Washington University School of Medicine in St. Louis have identified a parasite protein that has all the makings of a microbial glass jaw: it's essential, it's vulnerable and humans have nothing like it, meaning scientists can take pharmacological swings at it with minimal fear of collateral damage.

20 May 2010

Zebrafish may help scientists reveal function of mysterious enzyme linked to steroid cortisol

Michael E. Baker, PhD, a researcher at the University of California, San Diego School of Medicine has discovered that zebrafish - an important animal model in disease and environmental studies - could provide the means to help scientists eventually reveal the function of a mysterious enzyme linked to the steroid cortisol, and found in the human brain.

20 May 2010

Kansas State University researcher awarded NIH grant to study antibiotic-resistant bacteria

Antibiotic-resistant bacteria are becoming a growing problem around the world, and are a particular worry in hospital-acquired infections.

20 May 2010

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Inviragen has announced the initiation of the first clinical trial of its vaccine to protect against dengue fever. The trial, to be conducted at Saint Louis University, is designed to assess the safety of Inviragen's investigational dengue vaccine.

20 May 2010

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.

20 May 2010

NeoStem, Vatican's Pontifical Council collaborate to expand raise awareness of adult stem cell therapies

NeoStem, Inc.,, an international biopharmaceutical company with operations in the US and China, and the Vatican's Pontifical Council for Culture, today announced a joint initiative that includes their charitable organizations to expand research and raise awareness of adult stem cell therapies.

19 May 2010

Immune System News and Research

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

European researchers define research priorities in biogerontology

New therapy program serves as foundation for ongoing clinical development

Researchers discover key gene that promotes development of common kidney cancer

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Vitamin D plays much wider role in people's life

HemaCare announces commercial cell therapy collection agreement with Dendreon

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study

Phase 1/2 clinical trial data of Oncophage for recurrent high-grade glioma

Research and movement in future towards universal influenza virus vaccine

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Live malaria parasites in the skin shut down immune responses and block vaccine function: Study

Update on Phase I clinical trials of Oncopore for treatment of cancer

Saint Louis University conducts research to find safe, effective vaccination for dengue

New study shows CDPK1 controls toxoplasma's ability to secrete microneme proteins

Zebrafish may help scientists reveal function of mysterious enzyme linked to steroid cortisol

Kansas State University researcher awarded NIH grant to study antibiotic-resistant bacteria

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Phase I study of SNS-032 demonstrates safety, potential clinical activity in treating B-cell malignancies

NeoStem, Vatican's Pontifical Council collaborate to expand raise awareness of adult stem cell therapies

Immunology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News